LOS ANGELES, March 5 Vista Partners announced today thatit has updated coverage and has issued a $3.52 price target on InovioBiomedical Corporation (Amex: INO). "Inovio has compelling pre-clinical andclinical data regarding the ability of their technology to significantlyenhance the potency of DNA vaccines, with positive interim human results fromthree independent clinical studies. The company's technology is furthervalidated from license agreements with two of the world's big five vaccinecompanies, Merck and Wyeth, plus multiple other partnerships andcollaborations," said Ross Silver, Director of Research for Vista Partners.For more information and to download the report, please visit the VistaPartners website at http://www.vistap.com.
About Vista Partners:
Vista Partners provides independent, equity research to institutional andindividual investors, with a focus on publicly traded small capitalizationcompanies. With offices in Los Angeles and San Francisco, Vista Partners isone of the fastest growing independently owned equity research firms. VistaPartners professional staff has backgrounds in finance, corporatecommunications and investment banking. More information is available athttp://www.vistap.com.
About Inovio Biomedical Corporation:
Inovio Biomedical (AMEX:INO) is focused on developing multiple DNA-basedimmunotherapies. Inovio is a leader in developing human applications ofelectroporation using brief, controlled electrical pulses to increase cellularuptake of a useful biopharmaceutical. Interim human data has shown thatInovio's DNA delivery technology can significantly increase gene expressionand immune responses from DNA vaccines. Immunotherapy partners include Merck,Wyeth, Vical, University of Southampton, Moffitt Cancer Center, the U.S. Army,National Cancer Institute, and International Aids Vaccine Initiative. Inovio'stechnology is protected by an extensive patent portfolio covering in vivoelectroporation. More information is available at http://www.inovio.com.Contact: Vista Partners LLC Ross Silver (415) 738-6229 [email protected]
SOURCE Vista Partners